Ankur Malpani

Ankur Malpani

Auto-generated profile, based on publicly available information

Ankur Malpani

Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
JPJoao G. Porto
Joao G. Porto
ABAnsh M. Bhatia
Ansh M. Bhatia
ABAbhishek Bhat
Abhishek Bhat
MAMaria Camila Suarez Arbelaez
Maria Camila Suarez Arbelaez
RBRuben Blachman-Braun
Ruben Blachman-Braun
HSHemendra N. Shah
Hemendra N. Shah
Purpose: The goal of this systematic review is to assess the temporal changes in outcomes and complications of transurethral resection of the prostate (TURP) from 2000 to 2022. Methods: We conducted a systematic review and meta-analysis of 103 randomized clinical trials from PubMed on TURP, involving 8521 patients. Studies were grouped by years: 2000–2004, 2005–2009, 2010–2014, and 2015–2022. We assessed International Prostate Symptom Score (IPSS), Peak Flow (Qmax), Post-void residue of urine (PVR), and post-operative complications. Heterogeneity was ranked as low (I2 < 25%), moderate (I2 = 25–75%), or high (I2 > 75%). Results: TURP significantly improved IPSS, Qmax, and PVR, with the most recent studies showing superior results in IPSS and Qmax after 3 years compared to 2000–2004 studies. Heterogeneity in PVR was high (I2 = 100%). No negative impact on erectile function was observed. Complication rates included TURP syndrome (2%), bleeding (8%), and blood transfusion (6%), but elevated heterogeneity with difference between the groups was seen in clot evacuation (I2 = 83%) and urinary tract infections (I2 = 82%). Other complications were urinary retention (4%), incontinence (8%), urethral stricture (3%), bladder neck stenosis (2%). Conclusion: In the last 20 years there has not been a clear trend in the results of TURP. The found heterogeneity may indicate a lack of standardization in TURP procedures. However, symptomatic improvement among patients is uniform, which supports this procedure as a historical benchmark surgical treatment for BPH.

24 January 2025 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
JPJoao G. Porto
Joao G. Porto
ABAnsh M. Bhatia
Ansh M. Bhatia
ABAbhishek Bhat
Abhishek Bhat
MAMaria Camila Suarez Arbelaez
Maria Camila Suarez Arbelaez
RBRuben Blachman-Braun
Ruben Blachman-Braun
HSHemendra N. Shah
Hemendra N. Shah
Purpose: To compare outcomes of transurethral resection of the prostate (TURP) across different regions worldwide over the past two decades. Methods: A systematic review and meta-analysis of randomized clinical trials indexed to PubMed that assessed TURP. A total of 102 studies with 8,454 patients were included and grouped by continents: Europe, Asia, Africa, and Others (North America, South America, and Australia). International Prostate Symptom Score (IPSS), peak flow (Qmax), postvoid residual urine (PVR), PSA levels, prostate volume, and Sexual Health Inventory for Men scores (at 3, 12, and 36 months) were assessed, along with postoperative complications. Heterogeneity across studies was classified as low (I 2 < 25%), moderate (I 2 = 25–75%), or high (I 2 > 75%). Results: TURP consistently exhibited significant enhancements in IPSS, Qmax, and PVR across various regions. Notably, PVR demonstrated high heterogeneity (I²=100%). TURP presented low complication rates with TURP syndrome (2%), bleeding (8%), and blood transfusion (6%). However, significant heterogeneity was observed, particularly for clot evacuation (I 2 = 87%), irritative symptoms (I 2 = 96%), and incontinence (I 2 = 84%). The retreatment rates at 1 and 3 years were 5% and 7%, respectively, with significant differences across regions. Conclusion: Global outcomes of TURP lack a discernible trend. The substantial heterogeneity observed among continents suggests a lack of standardization. Nevertheless, uniform symptomatic improvements among patients still support TURP as the gold-standard surgical treatment for benign prostatic hyperplasia, despite variations in its results worldwide.

27 February 2026 in BJU International
Verified
Journal Article
Open access
AMAnkur Malpani
Ankur Malpani
JRJonathan T. Ryan
Jonathan T. Ryan
HYHui Yu
Hui Yu
NSNachiketh Soodana‐Prakash
Nachiketh Soodana‐Prakash
AKArchan Khandekar
Archan Khandekar
SPSanoj Punnen
Sanoj Punnen
Objectives: To evaluate basal‐luminal cell of origin subtyping using Prediction Analysis of Microarray of 50 genes (PAM50) genomic classification profiles for predicting disease progression in men undergoing active surveillance (AS) for prostate cancer (PCa). Patients and Methods: In the prospective Miami Active Surveillance Trial (MAST) trial, 205 men undergoing AS received serial multiparametric magnetic resonance imaging (MRI) and biopsies, including MRI‐targeted and systematic sampling. The highest‐grade core from each biopsy was sent for expression profiling using Decipher, a clinical‐grade transcriptome assay (Veracyte Inc., San Diego, CA, USA). Basal‐luminal subtyping was evaluated using PAM50 molecular subtype models. PCa grade progression was compared across subtypes, as were gene mutation signatures, prognostic indices, and pathway activities. Kaplan–Meier curves, log‐rank test, and multivariable Cox regression were used to assess association between PAM50 and grade progression. Heatmaps and volcano plots were rendered to illustrate potential mechanistical differences between PAM50 subtypes. Results: Of the 205 patients, 128 had transcriptome data for baseline basal‐luminal classification. PAM50 identified 46 Luminal A (LA), 26 Luminal B (LB), and 56 Basal subtypes. Decipher scores were lowest in LA, followed by Basal, and highest in LB. Grade progression‐free survival was worse in patients with the LB subtype (median 1.7 years) compared to those with LA and Basal subtypes (median 2.9 years; log‐rank P = 0.005); LB patients had grade progression‐free survival of 34% by 24 months of AS, compared to 63% for Basal or 68% for LA. Transcriptome analysis showed distinct enrichment profiles for each subtype, with LB strongly associated with SPOP and CHD1 mutations. Limitations include small sample size and single‐institution setting. Conclusion: The PAM50 basal‐luminal subtyping shows promise as a molecular classification tool for predicting progression risk in PCa. This is one of the only prospective studies evaluating PAM50 subtyping for predicting cancer progression in a cohort of men undergoing AS for PCa.